Smith & Nephew shares experienced sharp downward pressure primarily after the medical technology group reduced its full-year underlying revenue growth guidance. Weaker-than-expected sales performance within its critical U.S. orthopedic divisions—specifically ongoing softness in U.S. knee implant demand and temporary headwinds affecting hip implants ahead of upcoming product introductions—missed consensus market estimates, triggering negative investor sentiment and a sell-off.